These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15177425)
41. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175 [TBL] [Abstract][Full Text] [Related]
42. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman RE; Calvert HA; Gamucci T; Twelves C; Fargeot P; Bottomley A; Eur J Cancer; 2004 May; 40(7):1021-30. PubMed ID: 15093577 [TBL] [Abstract][Full Text] [Related]
43. A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline. Ranade AA; Bapsy PP; Nag S; Raghunadharao D; Raina V; Advani SH; Patil S; Maru A; Gangadharan VP; Goswami C; Sekhon JS; Sambasivaiah K; Parikh P; Bakshi A; Mohapatra R Asia Pac J Clin Oncol; 2013 Jun; 9(2):176-81. PubMed ID: 23176568 [TBL] [Abstract][Full Text] [Related]
44. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Schwonzen M; Kurbacher CM; Mallmann P Anticancer Drugs; 2000 Oct; 11(9):681-5. PubMed ID: 11129728 [TBL] [Abstract][Full Text] [Related]
45. [Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast]. Ferrero JM; Magné N; Foa C; Largillier R; Namer M Bull Cancer; 2003 Mar; 90(3):219-26. PubMed ID: 12801824 [TBL] [Abstract][Full Text] [Related]
46. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Symon Z; Peyser A; Tzemach D; Lyass O; Sucher E; Shezen E; Gabizon A Cancer; 1999 Jul; 86(1):72-8. PubMed ID: 10391566 [TBL] [Abstract][Full Text] [Related]
47. Liposomal anthracyclines for breast cancer. Sparano JA; Winer EP Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228 [TBL] [Abstract][Full Text] [Related]
48. Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group. Pazos C; Mickiewicz E; Di Notto MR; Cóppola F; Ventriglia M; Jovtis S; Balbiani L; Lewi D; Róndinón M; Témperley G; Trigo M; Bertoncín AM; Pascual M; Uranga G; Cazap E; Breier S; Grasso S; Estévez R; Triguboff E; Alvarez A; Suárez A Breast Cancer Res Treat; 1999 May; 55(1):91-6. PubMed ID: 10472783 [TBL] [Abstract][Full Text] [Related]
49. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos D; Papadimitriou C; Linardou H; Aravantinos G; Papakostas P; Skarlos D; Kosmidis P; Fountzilas G; Gogas H; Kalofonos C; Dimopoulos AM Br J Cancer; 2004 Nov; 91(9):1639-44. PubMed ID: 15494721 [TBL] [Abstract][Full Text] [Related]
50. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325 [TBL] [Abstract][Full Text] [Related]
51. Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Rimassa L; Carnaghi C; Garassino I; Salvini P; Ginanni V; Gullo G; Morenghi E; Santoro A Breast Cancer Res Treat; 2003 Jan; 77(2):185-8. PubMed ID: 12602917 [TBL] [Abstract][Full Text] [Related]
52. [Use of adriablastine in the combined chemotherapy of breast cancer patients with bone metastases]. Korman DB; Borisov AI; Maslova IA; Dobroskok LB Vopr Onkol; 1980; 26(8):20-4. PubMed ID: 7415044 [TBL] [Abstract][Full Text] [Related]
53. [Paclitaxel versus doxorubicin in first-line therapy of metastatic breast carcinoma]. Tanner J; Kuhnt T Strahlenther Onkol; 2000 Sep; 176(9):435-6. PubMed ID: 11050920 [No Abstract] [Full Text] [Related]
54. [Combined mitoxantrone therapy for heavily pretreated metastatic breast cancer]. Yokoe T; Iino Y; Aoyagi H; Maemura M; Sugamata N; Takai Y; Horiguchi J; Ishida T; Morishita Y Gan To Kagaku Ryoho; 1993 Jan; 20(1):169-71. PubMed ID: 8422183 [No Abstract] [Full Text] [Related]
55. [A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases]. Kokufu I; Tanei T; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K Gan To Kagaku Ryoho; 2002 Apr; 29(4):585-8. PubMed ID: 11977543 [TBL] [Abstract][Full Text] [Related]
56. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Tejada-Berges T; Granai CO; Gordinier M; Gajewski W Expert Rev Anticancer Ther; 2002 Apr; 2(2):143-50. PubMed ID: 12113236 [TBL] [Abstract][Full Text] [Related]
57. Liposomal anthracyclines in metastatic breast cancer: clinical update. Rivera E Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590 [TBL] [Abstract][Full Text] [Related]
58. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Briasoulis E; Karavasilis V; Tzamakou E; Rammou D; Soulti K; Piperidou C; Pavlidis N Cancer Chemother Pharmacol; 2004 May; 53(5):452-7. PubMed ID: 14749894 [TBL] [Abstract][Full Text] [Related]
59. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Giotta F; Lorusso V; Maiello E; Filippelli G; Valerio MR; Caruso M; Verderame F; Latorre A; Colucci G Ann Oncol; 2007 Jun; 18 Suppl 6():vi66-9. PubMed ID: 17591836 [TBL] [Abstract][Full Text] [Related]
60. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]